Long non-coding RNA signatures to track treatment responses in multiple sclerosis
Long non-coding RNA signatures to track treatment responses in multiple sclerosis
批准号:
10088013
负责人:
Charles Floyd Spurlock
金额:
$50.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-10 至 2022-02-28
关键词:
AdoptedAdvocateAutoimmune DiseasesAutoimmunityBenefits and RisksBiologicalBiological MarkersBiological ProcessBloodBrainCardiacCerebrospinal FluidChronicClinicalCodeComplexDataDetectionDiagnosisDiseaseDisease remissionDoseEarly DiagnosisEarly InterventionEarly treatmentEuropeEventEvoked PotentialsExhibitsExpressed Sequence TagsExpression ProfilingFaceFoundationsGenesGenetic TranscriptionGoalsHealthHealthcareHealthcare SystemsHumanInflammatoryInvertebratesLaboratoriesMachine LearningMagnetic Resonance ImagingMeasuresMessenger RNAMonitorMultiple SclerosisNatureNervous System TraumaNeuraxisNeurologistOligoclonal BandsOpportunistic InfectionsOrganismOutcomePaperPatient CarePatient MonitoringPatient-Focused OutcomesPatientsPatternPeripheralPersonal SatisfactionPersonsPharmaceutical PreparationsPhasePositioning AttributeProbabilityProteinsRNAReportingResearchRestSiteSpecialistSpinal CordSuggestionSymptomsTestingTherapeuticTimeTissuesTreatment FailureTreatment Side EffectsUnited StatesUntranslated RNAVertebratesWhole BloodWorkadverse drug reactionaggressive therapybasebrain healthcandidate markercell typeclinical subtypescohortcostdifferential expressiondisabilitydisorder controldrug efficacyeffective therapyexperimental grouphealth organizationhuman diseaselearning classifiermultiple sclerosis patientnervous system disordernoveloptimal treatmentsoutcome forecastpatient populationphase 2 studypreservationresponsetreatment response
中文摘要
摘要
多发性硬化症的早期发现是限制神经损伤的关键,
患者进展和对治疗的反应可以说是相似的,如果不是更重要的话,
疾病的慢性本质。此外,据报道,
在患者人群中高达25%至40%,这表明需要提供连续的
监测和选择最佳治疗。新的可操作生物标志物的鉴定将
为临床医生提供额外的信息,用于诊断、预后、临床
分型以及用于治疗的选择和监测。启动次优治疗
对病人的健康和经济状况都是有害的。
迄今为止,选择疾病缓解治疗(DMT)的一般方法是权衡
风险和益处,同时考虑疾病的侵袭性,药物的疗效和
以“试错法”的方式来评估治疗的潜在副作用。这种做法相当令人不安
当理解治疗失败或不充分可能导致不可逆的神经系统疾病时,
损害此外,这些药物中的许多与严重的药物不良反应有关
如心脏病、机会性感染和继发性自身免疫。选择
对特定患者的最佳治疗以及确定特定治疗是否/何时有效的能力
DMT的减少是非常可取的,并将在整个医疗保健的巨大利益
江西篇章MS疾病的病程并非在所有患者中表现相同,也不是所有患者
对治疗的反应是一样的。鉴定可操作的生物标志物以作为
一种特定治疗的疗效替代物将允许临床医生识别无反应的
尽可能早地评估给药或给药,以优化患者
结果。
我们以前的工作已经探索了lncRNA作为候选生物标志物,可以在
外周全血准确分类MS的初步数据提供了支持我们的
快速通道应用突出了用机器分析lncRNA表达水平的潜力
学习不仅对MS进行分类,而且还指示治疗反应。
英文摘要
ABSTRACT
Early detection of multiple sclerosis is key to limiting neurological damage but monitoring
patient progression and response to therapy is of arguably similar if not greater importance due
to the chronic nature of disease. Moreover, rates of non-adherence to therapy has been reported
to be as high as 25% to 40% in the patient population suggesting the need to provide continuous
monitoring and selection of optimal therapy. Identification of novel actionable biomarkers would
provide clinicians with additional information for the purposes of diagnosis, prognosis, clinical
subtyping as well as for the selection and monitoring of therapy. Initiation of sub-optimal therapy
can be both detrimental to the patient’s health and financial well-being.
To date, the general approach to selecting a disease modifying treatment (DMT) is to weigh
the risks and benefits while considering the aggressiveness of disease, efficacy of the drug and
the potential side effects of treatment in a “trial and error” fashion. This approach is quite unsettling
when understanding that treatment failure or inadequacy can cause irreversible neurological
damage. Furthermore, many of these drugs are associated with serious adverse drug reactions
such as cardiac events, opportunistic infections and secondary autoimmunity. Selection of the
best therapy for a particular patient as well as the ability to identify if/when efficacy of a particular
DMT dwindles is highly desirable and would be of great benefit throughout the healthcare
spectrum. The course of MS disease does not manifest identically in all patients nor do all patients
respond to treatment the same way. Identification of actionable biomarkers to serve as a
surrogate for the efficacy of a particular therapy would allow clinicians to identify nonresponsive
patients as early as possible and potentially evaluate dosing or administration to optimize patient
outcomes.
Our previous work has explored lncRNAs as candidate biomarkers that can be measured in
peripheral whole blood to accurately classify MS. The preliminary data provided in support of our
fast track application highlights the potential for lncRNA expression levels analyzed with machine
learning to not only classify MS but also indicate treatment responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis
-
批准号:10478749
-
项目类别:
-
资助金额:$24.83万
-
财政年份:2022
-
负责人:Charles Floyd Spurlock
-
依托单位:
海外基金